148 related articles for article (PubMed ID: 32994204)
1. Resolution of Spatial and Temporal Heterogeneity in Bevacizumab-Treated Breast Tumors by Eigenspectra Multispectral Optoacoustic Tomography.
Liapis E; Klemm U; Karlas A; Reber J; Ntziachristos V
Cancer Res; 2020 Dec; 80(23):5291-5304. PubMed ID: 32994204
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic effects on breast tumor hemodynamics revealed by eigenspectra multispectral optoacoustic tomography (eMSOT).
Liapis E; Karlas A; Klemm U; Ntziachristos V
Theranostics; 2021; 11(16):7813-7828. PubMed ID: 34335966
[TBL] [Abstract][Full Text] [Related]
3. Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry.
Quiros-Gonzalez I; Tomaszewski MR; Aitken SJ; Ansel-Bollepalli L; McDuffus LA; Gill M; Hacker L; Brunker J; Bohndiek SE
Br J Cancer; 2018 Apr; 118(8):1098-1106. PubMed ID: 29576623
[TBL] [Abstract][Full Text] [Related]
4. Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.
Quiros-Gonzalez I; Tomaszewski MR; Golinska MA; Brown E; Ansel-Bollepalli L; Hacker L; Couturier DL; Sainz RM; Bohndiek SE
Cancer Res; 2022 Apr; 82(8):1658-1668. PubMed ID: 35404400
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model.
El-Hajjar L; Jalaleddine N; Shaito A; Zibara K; Kazan JM; El-Saghir J; El-Sabban M
Cell Signal; 2019 Jan; 53():400-412. PubMed ID: 30445167
[TBL] [Abstract][Full Text] [Related]
6. Eigenspectra optoacoustic tomography achieves quantitative blood oxygenation imaging deep in tissues.
Tzoumas S; Nunes A; Olefir I; Stangl S; Symvoulidis P; Glasl S; Bayer C; Multhoff G; Ntziachristos V
Nat Commun; 2016 Jun; 7():12121. PubMed ID: 27358000
[TBL] [Abstract][Full Text] [Related]
7. Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy.
Rebelo de Almeida C; Mendes RV; Pezzarossa A; Gago J; Carvalho C; Alves A; Nunes V; Brito MJ; Cardoso MJ; Ribeiro J; Cardoso F; Ferreira MG; Fior R
Commun Biol; 2020 Jun; 3(1):299. PubMed ID: 32523131
[TBL] [Abstract][Full Text] [Related]
8. Volumetric Optoacoustic Imaging Unveils High-Resolution Patterns of Acute and Cyclic Hypoxia in a Murine Model of Breast Cancer.
Ron A; Deán-Ben XL; Gottschalk S; Razansky D
Cancer Res; 2019 Sep; 79(18):4767-4775. PubMed ID: 31097477
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
[TBL] [Abstract][Full Text] [Related]
11. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
Franco M; Man S; Chen L; Emmenegger U; Shaked Y; Cheung AM; Brown AS; Hicklin DJ; Foster FS; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3639-48. PubMed ID: 16585189
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic drugs increase xenograft aggressiveness.
Cancer Discov; 2012 Mar; 2(3):OF3. PubMed ID: 22586000
[TBL] [Abstract][Full Text] [Related]
13. Novel strategies towards the use of anti-angiogenic agents in breast cancer.
Bakker JL; Meijers-Heijboer H; Verheul H
Eur J Pharmacol; 2013 Oct; 717(1-3):36-9. PubMed ID: 23545363
[TBL] [Abstract][Full Text] [Related]
14. Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.
Hutchinson LG; Mueller HJ; Gaffney EA; Maini PK; Wagg J; Phipps A; Boetsch C; Byrne HM; Ribba B
CPT Pharmacometrics Syst Pharmacol; 2016 Nov; 5(11):636-645. PubMed ID: 27863175
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
Zhu W; Kato Y; Artemov D
PLoS One; 2014; 9(1):e86583. PubMed ID: 24466160
[TBL] [Abstract][Full Text] [Related]
16. High-Resolution Multispectral Optoacoustic Tomography of the Vascularization and Constitutive Hypoxemia of Cancerous Tumors.
Chekkoury A; Nunes A; Gateau J; Symvoulidis P; Feuchtinger A; Beziere N; Ovsepian SV; Walch A; Ntziachristos V
Neoplasia; 2016 Aug; 18(8):459-67. PubMed ID: 27566102
[TBL] [Abstract][Full Text] [Related]
17. Deep Learning-Based Spectral Unmixing for Optoacoustic Imaging of Tissue Oxygen Saturation.
Olefir I; Tzoumas S; Restivo C; Mohajerani P; Xing L; Ntziachristos V
IEEE Trans Med Imaging; 2020 Nov; 39(11):3643-3654. PubMed ID: 32746111
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
19. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
[TBL] [Abstract][Full Text] [Related]
20. Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.
Ueda S; Kuji I; Shigekawa T; Takeuchi H; Sano H; Hirokawa E; Shimada H; Suzuki H; Oda M; Osaki A; Saeki T
PLoS One; 2014; 9(6):e98715. PubMed ID: 24905225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
